Recent research indicates that SYCP2 plays a crucial role in the initial development of human papillomavirus (HPV)-positive oropharyngeal cancer and has potential as both an early diagnostic biomarker and therapeutic target. SYCP2 stands out among specific biomarkers and molecular pathways linked to HPV-positive oropharyngeal cancer which influence cancer development.
| Project |
Description |
| Gene name |
SYCP2 (Synaptonemal Complex Protein 2) |
| Main function |
Chromosome pairing, usually expressed in meiosis |
| Role in HPV+ OPSCC |
Ectopic high expression, may promote carcinogenesis |
| Clinical significance |
Early screening marker, potential therapeutic target |
Related Product
Role and Function of SYCP2
SYCP2 emerges as a protein that becomes mostly active during meiosis while operating primarily in germ cells and shows scarce expression in somatic cells. SYCP2 forms part of the synaptonemal complex and plays a crucial role in both chromosome pairing and gene recombination. Studies on SYCP2 show potential strategies for developing targeted treatments for oropharyngeal cancer. Creating drugs that specifically target SYCP2 could lead to better treatment results and improved patient outcomes.
Fig 1. Putative mechanism of interaction between SYCP2 and human papillomavirus-positive oropharyngeal squamous cell carcinoma (Masterson, L., et al. 2015).
Relationship between SYCP2 and HPV-positive Oropharyngeal Cancer
Ectopic Expression
Research studies demonstrate that SYCP2 expression levels are abnormally high in HPV-positive oropharyngeal cancer. Normal oropharyngeal tissue shows minimal SYCP2 expression levels while this protein becomes highly expressed in lesions caused by HPV infection pointing to its possible role in cancer development.
HPV Carcinogenic Mechanism
The E6/E7 protein from high-risk HPV types like HPV-16 disrupts host cell cycle control mechanisms. Research indicates that epigenetic changes caused by HPV lead to SYCP2 expression activation.
Early Biomarker Potential
The activation of SYCP2 occurs during precancerous stages and early cancer development which suggests its potential use as an early diagnostic marker. Detecting SYCP2 expression levels in oral swabs enables the diagnostic process for HPV-related precancerous lesions.
Abnormal Expression in HPV-positive Head and Neck Cancer
The gene should remain inactive in healthy somatic cells. Multiple research studies demonstrate a reactivation of SYCP2 expression within HPV-positive head and neck cancers particularly in oropharyngeal cancer. The E7 protein from HPV leads to epigenetic reprogramming which results in the abnormal expression of this gene.
| Function |
Description |
| Carcinogenesis |
SYCP2 can promote cell cycle progression and inhibit apoptosis, and may promote carcinogenesis through mechanisms related to chromosome stability |
| Early events |
It is highly expressed in precancerous lesions, indicating that it plays a role in the early stages of tumorigenesis |
| Cellular localization |
It is mainly located in the cell nucleus and co-expressed with cell proliferation hotspots |
SYCP2 Targeted Therapy
Targeted therapy strategies are expected to be developed for the expression regulation pathway of SYCP2. It may be used as an immunotherapy target because it is lowly expressed in normal somatic cells and has certain cancer tissue specificity. Although SYCP2 is not a traditional oncogene, it has the following targeted therapeutic potentials due to its high tissue-specific expression and cancer tissue-specific expression:
Epigenetic Regulatory Targets
Activation of SYCP2 may be associated with loss of DNA methylation and changes in histone modifications. Use demethylating drugs (such as 5-azacytidine) or HDAC inhibitors (such as vorinostat) to regulate its expression. Intervene in the activation mechanism of SYCP2 to block its carcinogenesis-related functions.
Antigen Targeted Immunotherapy
SYCP2 is a typical cancer-testis antigen, expressed in cancer tissues and testis, and silent in other normal tissues. It has the potential to become a target for cancer vaccines or T cell immunotherapy.
Therapeutic Strategies
Develop peptide vaccines or TCR-T cell therapies targeting SYCP2. Combined with PD-1/PD-L1 inhibitors to enhance anti-tumor immune response.
Small Molecule Inhibitor Development
There are no known small molecule drugs that directly inhibit SYCP2 function. If it is determined that its oncogenic function depends on certain protein interactions (such as with chromosome regulatory proteins), intervention can be performed by blocking these interactions.
RNA Targeted Therapy
SiRNA or shRNA targeting SYCP2 mRNA can reduce its expression and inhibit tumor cell growth. It can be used in viral vectors or nanoparticle systems for targeted delivery.
References
- Masterson, L., et al. Deregulation of SYCP 2 predicts early stage human papillomavirus‐positive oropharyngeal carcinoma: A prospective whole transcriptome analysis. Cancer science. 2015, 106(11): 1568-1575.
- Billmyre, K., et al. SYCP1 head-to-head assembly is required for chromosome synapsis in mouse meiosis. Science Advances. 2023, 9(42): eadi1562.
.
